Drugs / epigallocatechin-3-gallate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01481818 | Sep 2011 → Jun 2022 | mucositis, radiodermatitis | Shandong Cancer Hospital and Institute | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | epigallocatechin-3-gallate | “Although acceleration of normal tissue protection using epigallocatechin-3-gallate (EGCG) has been reported, its actual clinical practicability remains obscure.” PMID 24444526 ↗ Jan 2014 |
| Known as | EGCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01481818 ↗ |
| Route | Topical | “Apply about 0.05ml/cm2 EGCG with different concentration topically for 3 times a day during radiotherapy” NCT01481818 ↗ |